Normal reproductive capacity of heifers that originated from in vitro fertilized embryos cultured with an antiviral compound.
Bovine viral diarrhea virus (BVDV) can associate with in vitro fertilized (IVF) bovine embryos despite washing and trypsin treatment. An antiviral compound, DB606 (2-(4-[2-imidazolinyl]phenyl)-5-(4-methoxyphenyl)furan), inhibits the replication of BVDV in bovine uterine tubal epithelial cells, Madin Darby bovine kidney cells, and fetal fibroblast cells. As well, DB606 in in vitro culture medium does not affect embryonic development. Antiviral-treated-IVF embryos placed into recipients developed into clinically normal calves. The objective of this project was to determine if these resultant heifer calves were capable of reproducing. Seven heifers from each of the treatment groups (natural breeding, IVF embryo, and IVF embryo cultured in DB606) of the previous study were used. At 20-27 months of age, the heifers were exposed to a fertile bull in a single pasture during a 63 d breeding season. Five of the seven heifers originating from natural breeding were pregnant 35 d after removal of the bull and calved. All of the heifers resulting from transfer of untreated IVF embryos were pregnant at 35 d; however, one aborted the fetus at 5-7 months of gestation. All of the heifers derived from transfer of IVF embryos cultured in DB606 were pregnant and calved. Offspring from dams of all treatment groups were clinically normal at birth. Adjusted 205 d weaning weights were not significantly different among the offspring of the treated and untreated dams. These results indicate that culture of bovine-IVF embryos in DB606 does not impair future reproductive capacity of resulting heifers.
Givens
M Daniel
MD
Department of Pathobiology, College of Veterinary Medicine, 127 Sugg Laboratory, Auburn University, Auburn, AL 36849, USA. givenmd@vetmed.auburn.edu
Marley
Mylissa S D
MS
Riddell
Kay P
KP
Galik
Patricia K
PK
Stringfellow
David A
DA
D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001912:Bovine Virus Diarrhea-Mucosal Disease / Q000188:drug therapy / Q000196:embryology*; D002417:Cattle / Q000196:embryology / Q000502:physiology; D001908:Diarrhea Viruses, Bovine Viral; D004526:Efficiency / Q000187:drug effects; D046149:Embryo Culture Techniques / Q000662:veterinary; D004622:Embryo, Mammalian / Q000187:drug effects* / Q000502:physiology / Q000821:virology; D005260:Female; D005307:Fertilization in Vitro / Q000379:methods; D005663:Furans / Q000494:pharmacology / Q000627:therapeutic use; D048288:Imidazolines / Q000494:pharmacology / Q000627:therapeutic use; D011247:Pregnancy; D018873:Pregnancy Rate; D011297:Prenatal Exposure Delayed Effects / Q000503:physiopathology* / Q000662:veterinary / Q000821:virology; D012098:Reproduction / Q000187:drug effects* / Q000502:physiology
C513035:2-(4-(2-imidazolinyl)phenyl)-5-(4-methoxyphenyl)furan; D000998:Antiviral Agents; D005663:Furans; D048288:Imidazolines